6月4日，联合健康盘前上涨3.17%，报388.0美元/股，成交额550.68万美元。
消息面上，美银证券将联合健康评级从中性上调至买入，目标价设定为450美元，较当前股价隐含约16%的上行空间。近期多家机构密集上调该股目标价：Truist将目标价从395美元上调至440美元并维持买入评级，奥本海默亦将目标价从405美元上调至420美元。据FactSet统计，分析师对该股的平均评级为"超配"，平均目标价约404美元。
基本面方面，联合健康旗下UnitedHealthcare近期宣布将在年底前取消约三分之二针对18岁以下会员的医疗预授权要求，此举被市场视为有助于提升患者满意度并优化行政成本，对公司中长期运营效率形成支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.